Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab has improved the treatment response and survival of patients with DLBCL. The introduction of rituximab biosimilar into healthcare system has helped...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Reena, Bhat, Gull Mohammad, Agrawal, Narendra, Sengar, Manju, Malhotra, Pankaj, Nityanand, Soniya, Lele, Chitra, Reddy, Pramod, Kankanwadi, Suresh, Maharaj, Narendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580068/
https://www.ncbi.nlm.nih.gov/pubmed/37854680
http://dx.doi.org/10.3389/fonc.2023.1248723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580068/
https://www.ncbi.nlm.nih.gov/pubmed/37854680
http://dx.doi.org/10.3389/fonc.2023.1248723

Ejemplares similares